TNXP
Companies
NASDAQ
Tonix Pharmaceuticals Holding Corp.
Health Care
$34.32
+$1.34 (+4.06%)
Price Chart
Overview
About TNXP
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
Market Cap
$9.9M
Volume
7.6M
Avg. Volume
19.1M
P/E Ratio
-0.9673245
Dividend Yield
0.00%
Employees
100.0
Company Information
Latest News for TNXP
Risk & Correlation Analysis
Market Correlation
1.18
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, TNXP shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$9.9M
Volume7.6M
P/E Ratio-0.97
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025